ประสิทธิผลของการใช้ยากลุ่ม SGLT-2 inhibitors ในผู้ป่วยโรคเบาหวานชนิดที่ 2 โรงพยาบาลพังโคน
คำสำคัญ:
ยากลุ่ม SGLT-2 inhibitors , TBSRTC, ประสิทธิผลของการรักษาบทคัดย่อ
This retrospective analytical study aimed to evaluate the effectiveness of SGLT-2 inhibitors in patients with type 2 diabetes mellitus (T2DM) attending the Non-Communicable Diseases (NCD) Clinic at Phang Khon Hospital, Sakon Nakhon Province. Data were collected from the medical records of 86 T2DM patients who had continuously received SGLT-2 inhibitors for at least 1 year. The studied parameters included body weight, body mass index (BMI), fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), serum creatinine, and estimated glomerular filtration rate (eGFR). Baseline data were analyzed using descriptive statistics. Outcome comparisons were performed using the Friedman test (statistical significance set at p < 0.05) and the Wilcoxon signed-rank test (statistical significance set at p < 0.0167 using Bonferroni correction).
The results showed that overall body weight and BMI significantly decreased ( = 66.14, df = 2, p < 0.001, and
= 67.82, df = 2, p < 0.001, respectively). FPG and HbA1c levels also showed statistically significant reductions (
= 18.50, df = 2, p < 0.001, and
= 7.13, df = 2, p = 0.027, respectively). Conversely, serum creatinine levels significantly increased (
= 21.61, df =2, p < 0.001), while eGFR significantly decreased (
= 30.24, df=2, p < 0.001). However, the median eGFR at all follow-up time points remained within the normal range (Median T1 = 90.71 mL/min/1.73 m2, IQR 69.95–100.70; Median T2 = 84.83 mL/min/1.73 m2, IQR 66.31–97.68; Median T3 = 80.92 mL/min/1.73 m2, IQR 61.98–97.49). Regarding adverse drug reactions, hypoglycemia and urinary tract infections were reported in 3.5% and 2.3% of the patients, respectively.
เอกสารอ้างอิง
สถาบันวิจัยระบบสาธารณสุข. สำรวจสุขภาพประชาชนไทยครั้งที่ 7 ชี้ NCDs ยังพุ่ง บอร์ด สวรส. ชี้ทิศทางนโยบายแก้ปัญหา NCDs ตรงจุดและเกิดผลกระทบต่อการแก้ปัญหาระบบสุขภาพ [อินเทอร์เน็ต]. [เข้าถึงเมื่อ 28 พฤศจิกายน 2568]. เข้าถึงได้จาก: https://www.hsri.or.th/news/1/4490
Cao Z, Cooper ME. Pathogenesis of diabetic nephropathy. J Diabetes Investig 2011;2(4):243-247.
Karalliedde J, Gnudi L. Endothelial factors and diabetic nephropathy. Diabetes Care 2011;34 (Suppl 2):S291-296.
Bell S, Fletcher EH, Brady I, Looker HC, Levin D, Joss N, et al. End-stage renal disease and survival in people with diabetes: a national database linkage study. QJM 2015;108(2):127–34.
Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Randomized Controlled Trial 2019;393(10184):1937–1947.
Selby NM, Taal MW. An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines. Diabetes Obes Metab 2020;22Suppl 1:3–15.
Palmer BF, Clegg DJ. Euglycemia Ketoacidosis as a Complication of SGLT2 Inhibitor Therapy. Clin J Am Soc Nephol 2021;16(8):1284-1291.
Novikov A, Vallon V. Sodium glucose cotransporter 2 inhibition in the diabetic kidney: an update. CurrOpin Nephrol Hypertens 2016;25(1):50-58.
Schork A, Sanish J, Vosseler A, Jaghutriz BA, Heyne N, Peter A, et al. Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy. Cardiovasc Diabetol 2019;18(1):46.
Lee G, Oh SW, Hwang SS, Yoon JW, Kang S, Joh HK, et al. Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis. PloS One 2017;12(5):e0177646.
Wu JHY, Foote C, Blomster J, Toyama T, Perkovic V, Sundstrom J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. The lancet Diabetes & Endocrinology 2016;4(5):411-419.
Zhang XL, Zhu QQ, Chen YH, Li XL, Chen F, Huang JA, et al. Cardiovascular safety, long-term noncardiovascular safety, and efficacy of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: A systematic review and meta-analysis with trial sequential analysis. J Am Heart Assoc 2018;7(2):e007165.
สมาคมโรคเบาหวานแห่งประเทศไทย ในพระบรมราชูปถัมภ์สมเด็จพระเทพรัตนราชสุดาฯ สยามบรมราชกุมารี. แนวทางเวชปฏิบัติสำหรับโรคเบาหวาน 2566. กรุงเทพฯ: ศรีเมืองการพิมพ์; 2566.
List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose contransport inhibition with dapagliflozin in type 2 diabetes. Diabetes care 2009;32(4):650-657.
Thomas MC, Cherney DZ. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia 2018;61(10):2098-2107.
Zhang YJ, Han SL, Sun XF, Wang SX, Wang HY, Liu X, et al. Efficacy and safety of empagliflozin for type 2 diabetes mellitus: meta-analysis of randomized controlled trials. Medicine 2018;97(43):
e12843.
Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 2015;75(1):33-59.
American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024. Diabetes Care 2024;47(Suppl1):S158–S178.
Nauck MA. Update on developments with SGLT-2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther 2014;8:1335-1380.
Wanner C, Inzucchi SE, Lachin JM, Fitchett D, Eynatten MV, Johansen OE, et al. EMPA-REG OUTCOME Investigators Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375(4):323-334.
Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Systematic review and network meta-analysis. Diabetes Obes Metab 2016;18(8):783-794.
Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013;159(4):262-274.
Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013;27(5):473-478.
ดาวน์โหลด
เผยแพร่แล้ว
รูปแบบการอ้างอิง
ฉบับ
ประเภทบทความ
สัญญาอนุญาต
บทความที่ตีพิมพ์ถือว่าเป็นลิขสิทธิ์ของวารสารการแพทย์โรงพยาบาลสกลนคร การคัดลอกเพื่อพัฒนาเชิงวิชาการต้องได้รับการอ้างอิงอย่างถูกต้อง
